Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ONVO's Cash-to-Debt is ranked higher than
83% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. ONVO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ONVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: N/A Max: 43000
Current: No Debt
0.1
43000
Equity-to-Asset 0.93
ONVO's Equity-to-Asset is ranked higher than
96% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ONVO: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
ONVO' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.39  Med: 0.93 Max: 0.96
Current: 0.93
-7.39
0.96
Interest Coverage No Debt
ONVO's Interest Coverage is ranked higher than
88% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 55.24 vs. ONVO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ONVO' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 33.23
Beneish M-Score: 0.30
WACC vs ROIC
23.34%
-8735.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -915.73
ONVO's Operating Margin % is ranked lower than
93% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. ONVO: -915.73 )
Ranked among companies with meaningful Operating Margin % only.
ONVO' s Operating Margin % Range Over the Past 10 Years
Min: -5448.28  Med: -3955.84 Max: -778.53
Current: -915.73
-5448.28
-778.53
Net Margin % -911.80
ONVO's Net Margin % is ranked lower than
93% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. ONVO: -911.80 )
Ranked among companies with meaningful Net Margin % only.
ONVO' s Net Margin % Range Over the Past 10 Years
Min: -6820.05  Med: -4453.41 Max: -911.8
Current: -911.8
-6820.05
-911.8
ROE % -58.43
ONVO's ROE % is ranked lower than
73% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. ONVO: -58.43 )
Ranked among companies with meaningful ROE % only.
ONVO' s ROE % Range Over the Past 10 Years
Min: -120.28  Med: -69.58 Max: -58.43
Current: -58.43
-120.28
-58.43
ROA % -54.03
ONVO's ROA % is ranked lower than
74% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. ONVO: -54.03 )
Ranked among companies with meaningful ROA % only.
ONVO' s ROA % Range Over the Past 10 Years
Min: -3700  Med: -77.23 Max: -54.03
Current: -54.03
-3700
-54.03
ROC (Joel Greenblatt) % -989.76
ONVO's ROC (Joel Greenblatt) % is ranked lower than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. ONVO: -989.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ONVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11894.96  Med: -2682.13 Max: -989.76
Current: -989.76
-11894.96
-989.76
GuruFocus has detected 2 Warning Signs with Organovo Holdings Inc $ONVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ONVO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ONVO Guru Trades in Q1 2016

Paul Tudor Jones 29,872 sh (+0.31%)
» More
Q2 2016

ONVO Guru Trades in Q2 2016

Paul Tudor Jones 41,741 sh (+39.73%)
» More
Q3 2016

ONVO Guru Trades in Q3 2016

Jim Simons 82,063 sh (New)
Paul Tudor Jones 21,553 sh (-48.36%)
» More
Q4 2016

ONVO Guru Trades in Q4 2016

Paul Tudor Jones 31,035 sh (+43.99%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414    SIC: 2836
Compare:NAS:BASI, NYSE:BIO » details
Traded in other countries:4OR.Germany, ONVO.Switzerland, 0R02.UK,
Organovo Holdings Inc is a development-stage company. It is engaged in developing and commercializing functional human tissues.

Organovo Holdings Inc is incorporated in Delaware on April 2007. The Company is a development-stage company. It is engaged in developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intend to introduce a paradigm shift in the approach to the generation of three-dimensional human tissues, by utilizing its proprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition and architecture. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with research, including infectious disease agents.

Ratios

vs
industry
vs
history
PB Ratio 4.55
ONVO's PB Ratio is ranked lower than
59% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. ONVO: 4.55 )
Ranked among companies with meaningful PB Ratio only.
ONVO' s PB Ratio Range Over the Past 10 Years
Min: 2.05  Med: 8.21 Max: 63.4
Current: 4.55
2.05
63.4
PS Ratio 73.81
ONVO's PS Ratio is ranked lower than
95% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. ONVO: 73.81 )
Ranked among companies with meaningful PS Ratio only.
ONVO' s PS Ratio Range Over the Past 10 Years
Min: 69.29  Med: 262 Max: 1744
Current: 73.81
69.29
1744
EV-to-EBIT -7.00
ONVO's EV-to-EBIT is ranked lower than
99.99% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. ONVO: -7.00 )
Ranked among companies with meaningful EV-to-EBIT only.
ONVO' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.6  Med: -7.5 Max: 46.4
Current: -7
-25.6
46.4
EV-to-EBITDA -7.21
ONVO's EV-to-EBITDA is ranked lower than
99.99% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. ONVO: -7.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
ONVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26  Med: -7.8 Max: 44.8
Current: -7.21
-26
44.8
Current Ratio 16.20
ONVO's Current Ratio is ranked higher than
98% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. ONVO: 16.20 )
Ranked among companies with meaningful Current Ratio only.
ONVO' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 13.23 Max: 34
Current: 16.2
0.04
34
Quick Ratio 16.13
ONVO's Quick Ratio is ranked higher than
98% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. ONVO: 16.13 )
Ranked among companies with meaningful Quick Ratio only.
ONVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 13.21 Max: 34
Current: 16.13
0.04
34
Days Inventory 159.60
ONVO's Days Inventory is ranked lower than
81% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. ONVO: 159.60 )
Ranked among companies with meaningful Days Inventory only.
ONVO' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 159.6
Current: 159.6
0
159.6
Days Sales Outstanding 94.79
ONVO's Days Sales Outstanding is ranked lower than
80% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. ONVO: 94.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
ONVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.4  Med: 56.58 Max: 94.79
Current: 94.79
49.4
94.79
Days Payable 340.92
ONVO's Days Payable is ranked higher than
94% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. ONVO: 340.92 )
Ranked among companies with meaningful Days Payable only.
ONVO' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 340.92
Current: 340.92
0
340.92

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.00
ONVO's Price-to-Net-Cash is ranked higher than
77% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.27 vs. ONVO: 5.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ONVO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.48  Med: 8.16 Max: 47.25
Current: 5
3.48
47.25
Price-to-Net-Current-Asset-Value 4.85
ONVO's Price-to-Net-Current-Asset-Value is ranked higher than
76% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.90 vs. ONVO: 4.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ONVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.44  Med: 8.02 Max: 42
Current: 4.85
3.44
42
Price-to-Tangible-Book 4.55
ONVO's Price-to-Tangible-Book is ranked higher than
61% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.19 vs. ONVO: 4.55 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ONVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.22  Med: 7.66 Max: 35.66
Current: 4.55
3.22
35.66
Price-to-Median-PS-Value 0.27
ONVO's Price-to-Median-PS-Value is ranked higher than
91% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. ONVO: 0.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ONVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.13 Max: 6.28
Current: 0.27
0.27
6.28
Earnings Yield (Greenblatt) % -14.29
ONVO's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. ONVO: -14.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ONVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14.29  Med: 2.6 Max: 3.9
Current: -14.29
-14.29
3.9

More Statistics

Revenue (TTM) (Mil) $3.97
EPS (TTM) $ -0.37
Beta2.79
Short Percentage of Float15.97%
52-Week Range $2.01 - 4.99
Shares Outstanding (Mil)104.41

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)